AstraZeneca said it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma in a deal valued at about $1.8 billion
AstraZeneca said it will pay $26 per CinCor share in cash, a premium of nearly 121% to the stock's closing price on Friday.
The offer also includes a non-tradable contingent value right of $10 per share in cash payable upon a specified regulatory submission of CinCor's baxdrostat, which is being developed to treat cardiorenal diseases.Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D'Souza
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
AstraZeneca PLC Will Buy CinCor for Cardiorenal AssetBy Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug...
Lire la suite »
NYC weather: Snow, rain could impact Monday morning commuteRain and snow Sunday night could impact your Monday morning commute.
Lire la suite »
Thousands of NYC nurses could walk off the job Monday, even after some hospitals reach agreementsThousands of NYC nurses could still walk off the job on Monday, even after some hospitals have reached agreements.
Lire la suite »
More rain coming to Southern California starting late MondayMore rain is coming to the Southland next week, forecasters said Saturday.
Lire la suite »
Clouds And Rain Sunday, Dry With Sunshine Monday - Alabama NewsSunday's forecast looks much different. Clouds increase Saturday night. Rain falls from a mainly cloudy sky at times Sunday. However, Sunday does not look like a washout. Rain amounts could be in the ballpark of one quarter inch.
Lire la suite »